Management reassured investors that there could be substantial value in its lead drug candidate, VK2735.

Novo Nordisk has lowered its full-year profit and sales forecasts amid slowed sales growth. However, a better-than-expected ...

Novo Nordisk's new CEO is set to face intense investor scrutiny this week as the Wegovy-maker shakes up its board and pursues ...

Pedersen, Maggie Fick and Bhanvi Satija COPENHAGEN (Reuters) -Wegovy-maker Novo Nordisk trimmed its full-year profit and ...

COPENHAGEN (Reuters) -Wegovy-maker Novo Nordisk lowered its full-year profit and sales forecasts again on Wednesday, in an ...

Another quarterly earnings announcement from Novo Nordisk and another downgrade to earnings guidance from the Danish ...

Earlier in the day, Novo Nordisk announced that it raised its acquisition bid to acquire Metsera, Inc. (NASDAQ:MTSR) for $10 ...

Novo Nordisk's new CEO said he was confident in the company's pipeline of obesity drugs, but that buying Metsera would allow ...

To read yesterday’s edition of Five things for pharma marketers to know, click here.

Novo Nordisk lowers its 2025 profit forecast as new CEO Mike Doustdar faces rising competition, leadership changes, and a ...

The latest of those is a bid valued at up to $10 billion for U.S. obesity-drug developer Metsera, up from a previous $9 billion offer it originally made, as it tries to usurp an already agree-on deal ...